Biopharma | June 29, 2025
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Extended lab space for product development, customer demos, and training
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Changhua site meets international regulatory standards for global medical applications
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Subscribe To Our Newsletter & Stay Updated
